NASDAQ · COCP

Cocrystal Pharma, Inc.

$0.92 +$0.02 (+2.07%) 1D Market open

Key Metrics

$12.41M
Market cap
P/E · TTM
$225.00K
Revenue · TTM
−$8.83M
Net income
EPS · TTM $-0.87
Dividend yield
Free cash flow
Beta · 1Y 1.53
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Apr 16 high, the share price fell 43%.

    Peak close $1.57 on Apr 16; trough close $0.90 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -43%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 13
    The stock moved +14.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 13
  • Apr 2
    The stock moved +48.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 2

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$12.41M
Enterprise value
Shares outstanding13.8M
52-wk range$0.86 – $2.67
Avg volume · 20D302.2K
Net cash
Book value / share$0.40
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Cocrystal Pharma, Inc.
IPO dateApr 1, 2008
Employees10

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S55.16
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -4,015.1%
Net -3,924.0%
FCF
ROE / ROIC -129.5% · —

Financial Health

Current ratio2.66
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$3.71M

Cash Flow · TTM

Operating CF −$7.59M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

-66.1
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings